合并症对心衰治疗有效性的影响:肺病与肾病
该回顾性队列研究评估了β受体阻滞剂在合并慢性肺病的心衰患者中的疗效,以及ACEI/ARB在合并慢性肾病的心衰患者中的疗效。结果显示,在HFrEF合并肺病患者中β受体阻滞剂可降低死亡和心衰住院风险,在HFpEF中无显著关联;ACEI/ARB对HFrEF和HFpEF合并肾病患者均保护 against 死亡、心衰住院和全因住院。
要点
- HFrEF合并慢性肺病者,β受体阻滞剂降低死亡风险(RR=0.58)和心衰住院风险(RR=0.78)。
- HFpEF合并慢性肺病者,β受体阻滞剂与结局无显著关联。
- HFrEF或HFpEF合并慢性肾病者,ACEI/ARB降低死亡、心衰住院和全因住院风险。
核心结论
- 在HFrEF合并慢性肺病患者中,β受体阻滞剂治疗对死亡和心衰住院有保护作用。
- 在HFpEF合并慢性肺病患者中,未观察到β受体阻滞剂与结局的显著关联。
- 在HFrEF或HFpEF合并慢性肾病患者中,ACEI/ARB对死亡、心衰住院和全因住院均有保护作用。
研究设计与样本
- 回顾性队列研究,采用新用户设计,分别评估β受体阻滞剂在心衰合并慢性肺病中的疗效以及ACEI/ARB在心衰合并慢性肾病中的疗效。
- 研究对象为社区中HFrEF或HFpEF个体;慢性肺病依据ICD-9编码490-496、518诊断;慢性肾病依据eGFR<60 mL/min per 1.73 m2纳入。
- 采用逆概率加权 pooled logistic marginal structural models,按心衰类型分层分析。
主要发现
- HFrEF合并慢性肺病者,β受体阻滞剂与死亡风险降低相关(RR=0.58,95%CI=0.44-0.77),与心衰住院风险降低相关(RR=0.78,95%CI=0.60-1.00)。
- HFpEF合并慢性肺病者,β受体阻滞剂与任何结局均无统计学显著关联。
- HFrEF合并慢性肾病者,ACEI/ARB与死亡风险降低(RR=0.60,95%CI=0.40-0.91)、心衰住院风险降低(RR=0.43,95%CI=0.28-0.67)和全因住院风险降低(RR=0.63,95%CI=0.45-0.89)相关。
- HFpEF合并慢性肾病者,ACEI/ARB与死亡风险降低(RR=0.52,95%CI=0.33-0.81)、心衰住院风险降低(RR=0.35,95%CI=0.18-0.68)和全因住院风险降低(RR=0.67,95%CI=0.47-0.95)相关。
关键数值与推荐
- 慢性肺病定义:ICD-9编码490-496、518。
- 慢性肾病定义:eGFR<60 mL/min per 1.73 m2。
- HFrEF合并慢性肺病:β受体阻滞剂死亡RR=0.58(95%CI=0.44-0.77),心衰住院RR=0.78(95%CI=0.60-1.00)。
- HFrEF合并慢性肾病:ACEI/ARB死亡RR=0.60(95%CI=0.40-0.91),心衰住院RR=0.43(95%CI=0.28-0.67),全因住院RR=0.63(95%CI=0.45-0.89)。
- HFpEF合并慢性肾病:ACEI/ARB死亡RR=0.52(95%CI=0.33-0.81),心衰住院RR=0.35(95%CI=0.18-0.68),全因住院RR=0.67(95%CI=0.47-0.95)。
临床怎么用
- 对HFrEF合并慢性肺病患者,β受体阻滞剂治疗可能降低死亡和心衰住院风险。
- 对HFpEF合并慢性肺病患者,β受体阻滞剂的获益不明确,需个体化评估。
- 对HFrEF或HFpEF合并慢性肾病患者,ACEI/ARB治疗可能降低死亡、心衰住院和全因住院风险。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the clinical effectiveness of beta-blocker therapy in individuals with heart failure (HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in individuals with HF and chronic kidney disease. DESIGN: Retrospective cohort study. SETTING: Community. PARTICIPANTS: Individuals with HF with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction (HFpEF). METHODS: We undertook separate new-user cohort studies to assess the effectiveness of beta-blocker therapy in treating HF and chronic lung disease and ACE-Is and ARBs in treating HF and chronic kidney disease (CKD). Individuals with a chronic lung disease diagnosis were included in the group with HF and chronic lung disease (International Classification of Diseases, Ninth Revision, codes 490-496, 518). Individuals with an estimated glomerular filtration rate less than 60 mL/min per 1.73 m2 were included in the group with HF and CKD. The clinical outcomes of interest were death from any cause, hospitalization for HF, and hospitalization for any reason. We fitted pooled logistic marginal structural models using inverse probability weighting, stratified according to HF type. RESULTS: For individuals with HFrEF with chronic lung disease, beta-blocker therapy was protective against death (relative risk (RR) = 0.58, 95% confidence interval (CI) = 0.44-0.77) and hospitalization for HF (RR = 0.78, 95% CI = 0.60-1.00). For those with HFpEF, no statistically significant associations between beta-blocker therapy use and any of the outcomes were observed. We found ACE-I and ARB use to be protective against all three outcomes of interest in individuals with HFrEF (death from any cause: RR = 0.60, 95% 0.40-0.91; hospitalization for HF: RR = 0.43, 95% CI = 0.28-0.67; hospitalization for any reason: RR = 0.63, 95% CI = 0.45-0.89, respectively) and those with HFpEF (death from any cause: RR = 0.52, 95% CI = 0.33-0.81; hospitalization for HF: RR = 0.35, 95% CI = 0.18-0.68; hospitalization for any reason: RR = 0.67, 95% CI = 0.47-0.95). CONCLUSION: Large observational studies may allow for identification of important subgroups of individuals with HF that might benefit from existing treatment approaches. Our findings may also better inform the design of more-definitive future observational studies and randomized trials.
引用
- Gurwitz JH, Magid DJ, Smith DH, et al. Treatment Effectiveness in Heart Failure with Comorbidity: Lung Disease and Kidney Disease. J Am Geriatr Soc. 2017. PMID: 28873219. doi:10.1111/jgs.15062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。